Scarica l'app Stockscreener
5.60
2.61%
-0.15
Dopo l'orario di chiusura:
5.56
-0.04
-0.71%
Precedente Chiudi:
$5.75
Aprire:
$5.78
Volume 24 ore:
877.29K
Relative Volume:
0.92
Capitalizzazione di mercato:
$280.56M
Reddito:
$124.00K
Utile/perdita netta:
$-49.99M
Rapporto P/E:
-3.3136
EPS:
-1.69
Flusso di cassa netto:
$-31.03M
1 W Prestazione:
-5.72%
1M Prestazione:
+6.06%
6M Prestazione:
+26.41%
1 anno Prestazione:
-30.35%
Intervallo 1D:
$5.55
$5.98
Intervallo di 1 settimana:
$5.365
$6.03
Portata 52W:
$3.785
$14.60
Candel Therapeutics Inc Stock (CADL) Company Profile
Nome
Candel Therapeutics Inc
Settore
Industria
Telefono
617-916-5445
Indirizzo
117 KENDRICK STREET, NEEDHAM
Confronta CADL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
5.60 | 297.61M | 124.00K | -49.99M | -31.03M | -1.69 |
|
ONC
Beone Medicines Ltd Adr
|
258.27 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 114.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.98 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
484.93 | 63.90B | 14.09B | 4.50B | 2.96B | 39.28 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-20 | Iniziato | Citigroup | Buy |
| 2025-02-19 | Iniziato | Canaccord Genuity | Buy |
| 2025-02-07 | Iniziato | BofA Securities | Buy |
| 2022-12-02 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-08-23 | Iniziato | Credit Suisse | Outperform |
| 2021-08-23 | Iniziato | Jefferies | Buy |
| 2021-08-23 | Iniziato | UBS | Buy |
Mostra tutto
Candel Therapeutics Inc Borsa (CADL) Ultime notizie
CADL to Present Phase 3 Prostate Cancer Trial Insights | CADL Stock News - GuruFocus
Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect? - Yahoo Finance
Deutsche Bank AG Boosts Stake in Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
Candel Therapeutics, Inc. (CADL)’s CAN-2409 Advances with FDA RMAT Status for Localized Prostate Cancer - MSN
CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer - sharewise
Candel Therapeutics (CADL) Gains on FDA RMAT Designation for CAN-2409 - GuruFocus
Candel Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:CADL - Benzinga
Candel Therapeutics gains FDA RMAT status for prostate cancer therapy By Investing.com - Investing.com South Africa
(CADL) Trading Report - news.stocktradersdaily.com
Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy: Retail Considers It Good Long-Term Buy By Stocktwits - Investing.com India
Small cap wrap: Midnight Sun Mining, MustGrow Biologics, Candel Therapeutics, HIVE... - Proactive financial news
Market movers: GameStop, Okta, Abercrombie, Candel Therapeutics... - Proactive financial news
Candel Says FDA Grants Regenerative Medicine Advanced Therapy Designation to Prostate Cancer Drug - marketscreener.com
Candel stock gains after FDA RMT designation (CADL:NASDAQ) - Seeking Alpha
Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy: Retail Considers It Good Long-Term Buy - MSN
Candel Therapeutics (CADL) Stock Is Surging Wednesday: What's Going On? - Benzinga
Candel Therapeutics get FDA’s RMAT designation for prostate cancer therapy - Proactive financial news
Candel Therapeutics (CADL) Receives RMAT Designation for CAN-2409 in Prostate Cancer | CADL Stock News - GuruFocus
Candel Therapeutics Receives FDA RMAT Designation for CAN-2409 - TipRanks
Candel Therapeutics gains FDA RMAT status for prostate cancer therapy - Investing.com
Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer - The Manila Times
Candel Therapeutics Receives FDA Regenerative Medicine - GlobeNewswire
Breakthrough: FDA Fast-Tracks Revolutionary Prostate Cancer Therapy Showing 80% Complete Response Rate - Stock Titan
Northern Trust Corp Purchases 6,250 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
Candel Therapeutics (CADL) to Reveal Positive Phase 3 Results fo - GuruFocus
Candel Therapeutics (CADL) to Reveal Positive Phase 3 Results for Prostate Cancer | CADL Stock News - GuruFocus
Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation - The Manila Times
Candel Therapeutics to Host Investor Conference Call - GlobeNewswire
Candel Therapeutics to host June 3 call on positive Phase 3 results for prostate cancer therapy - Proactive Investors
Wall Street Analysts Predict a 310.96% Upside in Candel Therapeutics (CADL): Here's What You Should Know - MSN
Candel Therapeutics: CAN-2409’s Promising Progress Deserves An Upgrade (NASDAQ:CADL) - Seeking Alpha
Candel Therapeutics, Inc. (CADL) to Present Positive Phase 3 Prostate Cancer Data at ASCO 2025 - MSN
Candel Therapeutics (NASDAQ:CADL) Upgraded at Wall Street Zen - Defense World
Small cap wrap: Excellon Resources, Candel Therapeutics, Forte Minerals... - Proactive financial news
Candel Therapeutics to present Phase 3 prostate cancer trial data at ASCO 2025 - Proactive financial news
Candel Therapeutics Unveils Promising Phase 3 Trial Results - TipRanks
Candel Therapeutics to Present Positive Phase 3 Clinical Trial Results of CAN-2409 for Prostate Cancer at ASCO 2025 - Nasdaq
Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025 - GlobeNewswire
Breakthrough Phase 3 Results: First Successful Prostate Cancer Trial in 20 Years Shows 30% Lower Recurrence Risk - Stock Titan
Best Momentum Stocks to Buy for May 19th - The Globe and Mail
New Strong Buy Stocks for May 19th - The Globe and Mail
CADL To Present Prostate Cancer Trial Data, RMD's Q3 Revenue Climbs 8%, AUNA On Watch... - RTTNews
Promising Pipeline Developments and Strong Data Support Buy Rating for Candel Therapeutics - TipRanks
Small cap wrap: Candel Therapeutics, Nevis Brands, Fineqia, Voyageur Pharmaceuticals, atai... - Proactive financial news
Candel Therapeutics Reports Strong Q1 2025 Results - TipRanks
CADL's Cash Reserves Projected to Last Until Early 2027 | CADL S - GuruFocus
Candel Therapeutics Stock Jumps On Upbeat Q1 Earnings: Retail Gets More Bullish - NewsBreak: Local News & Alerts
Candel Therapeutics Stock Jumps On Upbeat Q1 Earnings: Retail Gets More Bullish By Stocktwits - Investing.com India
Candel Therapeutics (CADL) Reports Q1 Earnings and Cash Reserves - GuruFocus
Market movers: Coinbase, Hertz, Candel Therapeutics, JD Sports... - Proactive Investors
Cardell Flat on Q1 - Baystreet.ca
Candel Therapeutics Inc Azioni (CADL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.00%
0.54%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):